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their vision (VA loss  ^  5 letters). A predictive value for better 
VA was found for younger age, better baseline VA, good re-
sponse on OCT and more frequent treatments.  Conclusion: 
At 3 years, intravitreal ranibizumab is able to maintain base-
line VA in exudative AMD patients, with a reduced number 
of injections, but not to show VA improvement, in clinical 
practice.  Copyright © 2013 S. Karger AG, Basel 
 Introduction 
 Neovascular age-related macular degeneration 
(nAMD) is a leading cause of irreversible blindness in 
people  6 50 years old in the developed world  [1] . It is ex-
pected that, by 2030, age-related macular degeneration 
(AMD) will be the most important cause of blindness in 
industrialized countries bypassing diabetic retinopathy 
or glaucoma.
 Ranibizumab (Lucentis  ) received the FDA approval 
in July 2006 and the EMEA approval in January 2007, 
and is currently indicated for use in nAMD based on the 
results presented by the phase III studies Minimally 
Classic/Occult Trial of Anti-Vascular Endothelial 
Growth Factor Antibody Ranibizumab in the Treatment 
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 Abstract 
 Purpose: To evaluate the 36-month efficacy of intravitreal 
ranibizumab injections for choroidal neovascularization sec-
ondary to age-related macular degeneration (AMD) in real 
world clinical practice.  Methods: Retrospective study involv-
ing 84 eyes of 77 patients; 52 eyes completed 3 years of fol-
low-up. Subjects were observed initially on a monthly basis 
and with extended follow-up intervals if signs of quiescence 
were detected, according to an established protocol. A com-
prehensive ophthalmologic examination was performed, in-
cluding best-corrected visual acuity (BCVA) determined with 
Early Treatment Diabetic Retinopathy Study charts, stereo-
scopic macular biomicroscopy and optical coherence to-
mography (OCT) with fluorescein angiography and indocya-
nine green angiography if considered necessary. Treatment 
was given if signs of active lesions were present.  Results: The 
mean baseline BCVA was 49.33 and 49.52 letters at the 
36-month visit. The average of treatments was 8.6 at 3 years. 
At this time point, 77% of treated eyes stabilized or improved 
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of Neovascular Age-Related Macular Degeneration 
(MARINA)  [2] and the Anti-Vascular Endothelial 
Growth Factor Antibody for the Treatment of the Pre-
dominantly Classic CNV in Age-Related Macular De-
generation (ANCHOR)  [3, 4] , which showed that month-
ly intravitreal injection of this drug resulted in visual 
stability in around 90–95% of treated patients and visual 
improvement in 1/3 of the cases. Few trials have been 
published presenting the visual outcomes of anti-vascu-
lar endothelial growth factor intravitreal injections in 
nAMD patients, and different dosing and time regimens 
were used  [5–10] . The long-term efficacy of ranibizumab 
in the treatment of exudative AMD in real world clinical 
practice is unknown.
 We conducted the present study in order to analyze the 
36-month outcomes of intravitreal ranibizumab injec-
tions given in an as-needed basis for choroidal neovascu-
larization (CNV) secondary to AMD in clinical practice.
 Methods 
 Study Design 
 A retrospective, nonrandomized institutional study was con-
ducted. Consecutive patients’ medical records were identified by 
the nAMD diagnosis from June 2006 to March 2009, and the fol-
lowing data were collected: age, gender, date of nAMD diagnosis, 
best-corrected visual acuity (BCVA) at each visit, f luorescein an-
giography (FA) and indocyanine green angiography (ICG) at 
baseline, optical coherence tomography (OCT) data at each visit.
 The major inclusion criteria were: (1) age 50 years or older; (2) 
active primary or recurrent macular neovascularization, whether 
predominantly classic (type 1 CNV), minimally classic or occult 
(type 2 CNV), secondary to AMD, juxtafoveal or subfoveal lesions 
and of all sizes; (3) any BCVA at baseline, and (4) a minimum 
follow-up of 12 months.
 The exclusion criteria were as follows: (1) polypoidal choroidal 
vasculopathy or retinal angiomatous proliferation (type 3 CNV); 
(2) secondary choroidal neovascularization not AMD related 
(high myopia, pseudohistoplasmosis, angioid streaks…); (3) other 
retinal pathologies such as vein or artery occlusions, juxtafoveal 
telangiectasias, choroidal tumors, familial macular dystrophies, 
trauma, or intraocular infection or inflammation; (4) retinal pig-
ment epithelium tear or ripping, and (5) any systemic contraindi-
cation to anti-VEGF or angiographic dyes. The preexisting car-
diovascular, cerebrovascular or peripheral vascular conditions 
were relative exclusion criteria.
 Eligible patients underwent a comprehensive ophthalmologic 
examination at baseline, including BCVA determined with Early 
Treatment Diabetic Retinopathy Study charts (ETDRS), stereo-
scopic macular biomicroscopy, OCT (Stratus OCT TM , Carl Zeiss 
Meditec, Dublin, Calif., USA, or Cirrus OCT, Cirrus TM HD-OCT, 
Carl Zeiss Meditec), FA and ICG (Retinal Camara TRC-50IX; 
Topcon Medical Systems Inc., Oakland, N.J., USA). The patients 
were monitored each 4 weeks with BCVA evaluation, ophthal-
moscopy and OCT (central macular thickness, CMT). The angio-
graphic evaluation (FA and ICG) was done in case of discrepancy 
between the clinical and morphological data.
 The major efficacy end points were the VA change from base-
line, the change on OCT-CMT measurements and the number of 
injections required over the 36-month period. OCT-CMT and 
BCVA changes were correlated with the following potential risk 
factors: age, baseline BCVA, baseline angiographic lesion types, 
number of treatments, presence of subfoveal serohemorrhagic 
retinal pigment epithelium detachment.
 When different OCT systems were used during the follow-up, 
a correction factor was introduced adding 60   m to the Stratus’s 
values before analyzing OCT results  [11] .
 Treatment Protocol 
 Intravitreal injections of ranibizumab were administered to 
all patients at baseline. No ‘loading dose’ (3 consecutive monthly 
injections) was given.
 Retreatment was recommended if: (1) new or persistent fluid 
was demonstrated on OCT; (2) an increase in CMT from previous 
lowest measurement due to fluid on OCT; (3) VA deterioration 
related to fluid on OCT, or (4) new or persistent signs of CNV ac-
tivity on fundus color photography, FA or ICG, including new 
hemorrhages, leakage on FA and/or early and late hyperfluores-
cence on ICG.
 A flexible strategy was adopted with additional reinjections 
administered according to the ‘retreatment criteria’. If clinical 
signs remained quiescent for 3 consecutive follow-up visits (no VA 
changes and dry macula), the intervals were extended to 8 weeks. 
If the stability was maintained after 6 months, the follow-up in-
tervals were extended to 12 weeks.
 Stratus or Cirrus OCT devices were used to evaluate the pres-
ence of fluid in the macula and identified as intraretinal fluid 
(cysts), subretinal fluid or fluid under the retinal pigment epithe-
lium (pigment epithelial detachment).
 Statistical Analysis 
 Statistical analysis was performed using the software PASW 
Statistics (SPSS, version 18.0, SPSS Inc., Chicago, Ill., USA).
 We evaluated the applicability of the assumptions of paramet-
ric tests, including normality of distributions by the Shapiro-
Wilk test and homogeneity of variances by Levene’s test, having 
verified the applicability of that statistical method for each situ-
ation, and when the assumptions were not met we applied the 
nonparametric equivalent test. For numerical variables we used 
the ANOVA/independent samples t test or their nonparametric 
equivalents. The within-eye comparison for the mean VA letter 
scores and the CMT measurements from baseline values was 
done using the paired-samples t test or the Wilcoxon signed-rank 
test. The influence of the baseline FA lesion types on the number 
of injections over 24 months was assessed using a one-way anal-
ysis of variance and the Kruskal-Wallis test. Outcome compari-
son between different groups was performed with Pearson’s   2 
test or Spearman’s correlation coefficients, and relative risk 
quantification was made with the odds ratio test, respecting the 
rules of Cochrane. Statistical significance was defined as p  ! 
0.05. The data were analyzed from all the patients enrolled in the 
study until their last VA and OCT findings. The censored or 
missing cases were handled with the last observation carried for-
ward method.
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 Results 
 Demographic Features 
 The study included 84 eyes of 77 patients, 49 women 
and 35 men, with an average age of 77.39 years (range, 
61–94) followed up for 34.3 months (SD 6.9). Of the 84 
eyes, 77 eyes attained 2 years of follow-up and 52 eyes 3 
years of follow-up. With respect to the baseline angio-
graphic lesion types, we found that 32.1% patients had 
predominantly classic, type 2 lesions, 22.6% minimally 
classic and 45.2% occult, type 1 lesions ( table 1 ).
 VA and OCT Changes 
 At baseline, the mean BCVA was 49.33 letters (SD 
15.17). At month 12, the improvement in mean and me-
dian VA scores compared to the baseline were +1.64 let-
ters (SD 12.8) and +1.0 letters, respectively. At month 24, 
the remaining 77 eyes showed a mean and median VA 
score compared with baseline of –1.25 (SD 16.95) and 
+2.0. At month 36 of follow-up, the 52 eyes had a mean 
and median VA score compared with baseline of –1.65 
(SD 18.7) and +1.0.
 On the first visit, 14 eyes (16.7%) had BCVA  ! 35 letters 
(20/200) and 10 (11.9%) had BCVA  1 70 letters (20/40). 
After 1 year of follow-up (n = 84), 14 eyes (16.7%) gained 
at least 3 lines of vision (15 letters), 56 eyes (66.7%) expe-
rienced stabilization (visual loss of less than 5 letters), 
whereas 6 eyes (7.14%) experienced BCVA loss of more 
than 15 letters. After 2 years of follow-up (n = 77), 10 eyes 
(13.0%) increased BCVA by 15 letters, 51 (66.2%) re-
mained unchanged, whereas 9 eyes (11.7%) experienced 
BCVA loss of more than 15 letters. After 3 years of follow-
up (n = 52), 8 eyes (15.4%) had an increased BCVA of  6 15 
letters; 32 (61.5%) experienced stabilization of BCVA loss, 
whereas 8 eyes (15.4%) experienced BCVA loss superior 
to 15 letters ( table 2 ).
 BCVA changes were not statistically significant in the 
Wilcoxon signed-ranks test (VA 0–12 months, p = 0.271; 
VA 0–24 months, p = 0.893) and paired-samples test (VA 
0–36 months, p = 0.526). BCVA changes by year are de-
picted in  table 3 .
 The OCT-CMT changes during the follow-up, how-
ever, did achieve the significance with a mean value of 
373.30   m (SD 102.67) at baseline, 296.33   m (SD 68.57) 
at 12 months (p  ! 0.001, paired samples test), 259.35   m 
(SD 67.93) at 24 months (p  ! 0.001, Wilcoxon signed-
ranks test) and 264.28   m (SD 67.68) at 36 months of 
follow-up (p  ! 0.001, paired samples test;  table 3 ).
 Correlation analyses between the change in OCT-
CMT and VA measurements were performed at different 
time points to analyze the predictive value of the OCT 
measurements. There was a statistically significant cor-
relation between the OCT-CMT measurements and the 
VA changes at month 24 (Spearman correlation,   = –0.25 
and p = 0.02) and 36 (Spearman correlation,   = –0.38 and 
p = 0.04). The overall improvement in VA was associated 
with a decrease in CMT.
 Vision loss was defined as a loss of at least 5 letters 
from the baseline at each time point. Thus, 28 eyes (33.3%) 
lost vision at 1 year of follow-up, 26 eyes (36.4%) at 2 years 
and 20 eyes (38.5%) lost vision at 3 years of follow-up.
 Vision loss was attributable to formation of subretinal 
fibrosis, progression of the underlying dry AMD or geo-
graphic atrophy with gradual vision loss. Seventeen pa-
tients (20%) finished with a disciform scar, the mean time 
for that occurrence being 22 months.
 Treatment Evaluation 
 The mean and range number of ranibizumab injec-
tions in the first, second and third years of follow-up was 
3.75 (SD 1.19; 1–6 treatments/eye), 2.64 (SD 1.73; 0–6 
treatments/eye) and 2.10 (SD 1.86; 0–6 treatments/eye), 
respectively. Eleven eyes (13.1%) required less than 3 in-
jections at 1 year of follow-up and 1 eye (1.3%) did so at 2 
years of follow-up.
Table 1.  Summary of demographic and baseline characteristics of 
the study patients (n = 84)
Sex
Male
Female
35 (41.7%)
49 (58.3%)
Age, years  
Mean 77.39
Range 61–94
CNV type, %
Predominantly classic
Minimally classic
Occult with no classic aspect
32.1
22.6
45.2
Previous therapy for AMD
None
PDT
67 (80.0%)
17 (20.2%)
Other pathologies
Epiretinal membrane
PDR
Glaucoma
3 (3.6%)
2 (2.4%)
5 (6.0%)
Follow-up, months
Mean 8 SD 34.386.9
Range 14–48
PDT = Photodynamic therapy; PDR = proliferative diabetic 
retinopathy.
D
ow
nl
oa
de
d 
by
: 
Fr
ei
e 
Un
ive
rs
itä
t B
er
lin
   
   
   
   
   
   
   
   
   
   
 
13
0.
13
3.
8.
11
4 
- 5
/1
5/
20
15
 4
:1
0:
40
 A
M
 Treatment of Exudative AMD with 
Intravitreal Ranibizumab 
 Ophthalmologica 2013;229:158–167 
 DOI: 10.1159/000343709 
161
 Sixty-eight eyes (88.31%) needed retreatment during 
the 2nd year of follow-up and 35 eyes (67.3%) did so dur-
ing the 3rd year.
 Risk Factor Analysis 
 There was a statistically significant correlation be-
tween the baseline VA and the final VA (p  ! 0.001, Pear-
son correlation r = 0.482). Twenty-three percent of the 
final VA is explained by the VA at baseline. We found that 
the worse final VA was correlated with the worse VA at 
baseline (VA  ! 35 letters; p  ! 0.001, independent samples 
t test). The better final VA (VA  1 70 letters) was statisti-
cally related with a younger age (p = 0.024) and a better 
baseline VA (p  ! 0.01, independent samples t test).
 We studied the good (mean change  6 +15 letters) and 
bad evolution (mean change  ^  –15 letters) according to 
different possible risk factors. The influence of the base-
line VA in the VA evolution was tested. The good evolu-
tion at 12 months was statistically related with the lower 
VA at baseline (p  ! 0.006, Mann-Whitney U test), but the 
baseline VA seems to have lost importance thereafter.
 The influence of baseline angiographic lesion types on 
the BCVA changes during the follow-up was also ana-
lyzed using a one-way parametric analysis of variance. 
None of the baseline angiographic subtypes were found 
to have any prognostic impact on the visual outcomes
(p  1 0.05, ANOVA;  fig. 1 ). However, we found a statisti-
cally significant difference between these groups in the 
OCT-CMT changes, with a better outcome of the pre-
dominantly classic membrane type (p  =  0.05, Kruskal-
Wallis test;  fig. 2 ). Similarly, no differences were found in 
the VA baseline parameters and visual outcomes between 
treatment-naive eyes (66 out of 84 eyes) and previously 
treated photodynamic therapy eyes (17 out of 84 eyes;
p  1 0.05, Student’s t test).
 Another risk factor identified for significant loss of 
BCVA was the presence of a subfoveal serohemorrhagic 
pigment epithelial detachment. Eight eyes presented with 
a serohemorrhagic pigment epithelial detachment, 4 of 
which had significant loss of BCVA at 36 months. This 
finding was not significant in a Pearson   2 test (p = 0.275); 
however, there is a tendency toward a worst evolution in 
this group with a relative risk of 2.42.
Table 2.  VA data
Loss of
≥30 letters
Loss of
≤15 letters
Mean gain
letters
Increase of
≥15 letters
VA ≤35
(20/200)
VA ≥60
(20/63)
VA ≥70
(20/40)
Baseline (n = 84) 16.7% (14) 27.4% (23) 11.9% (10)
12 months (n = 84) 1.2% (1) 92.9% (78) +1.64 [12.80]
–45 to 25 
16.6% (14) 21.4% (18) 36.9% (31) 13.1% (11)
24 months (n = 77) 5.2% (4) 88.3% (68) –1.25 [16.95]
–60 to 37 
13.0% (10) 24.7% (19) 32.5% (25) 16.9% (13)
36 months (n = 52) 7.7% (4) 84.6% (44) –1.65 [18.70]
–60 to 39
15.4% (8) 26.9% (14) 32.7% (17) 17.3% (9)
Figures in parentheses are numbers, those in square brackets are standard deviations.
Table 3.  VA, CMT and number of treatments throughout the follow-up (means 8 SD)
Baseline
(n = 84)
3 months
(n = 67)
12 months
(n = 84)
24 months
(n = 77)
36 months
(n = 52)
VA, letters 49.33815.17 52.57815.26 50.72815.94 48.79818.79 49.52819.72
CMT, m
Treatments, n
373.308102.67
–
314.228102.68
1.5380.53
296.33868.56
3.7581.20
259.35867.93
6.3582.3
264.28867.68
8.6783.3
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 The influence of the number of injections in the VA 
outcomes was assessed using a nonparametric correla-
tion analysis. A correlation was found between a higher 
number of injections and a better VA at 36 months of 
follow-up (p = 0.028, Kruskall-Wallis test;  fig. 3 ).
 We analyzed the pattern of VA evolution of treated pa-
tients and found that 39.3% of them had a VA gain at 6 
months that was maintained during the follow-up peri-
od; 16.7% showed an initial gain that was not maintained, 
and 44% of the patients had no initial gain. These pat-
terns of evolution were used for statistical analysis ( fig. 4 ). 
No statistically significant differences were detected be-
tween these groups of clinical evolution in the mean pa-
tient’s age, baseline angiographic lesion types, baseline 
VA, baseline CMT measurements or number of treat-
ments performed.
0
20
40
60
12 24 
Months
36Baseline
Predominantly classic (n = 27)
Minimally classic (n = 19)
Occult (n = 38)
 Fig. 1. BCVA evolution (letters ETDRS) in different baseline le-
sion subtypes. 
C
o
lo
r v
er
si
o
n 
av
ai
la
b
le
 o
n
lin
e
0
100
200
300
400
M
ea
n
 C
M
T 
(μ
m
)
Baseline 1 3 6 12 18
Month
24 30 36
Occult
Minimally classic
Predominantly classic
Membrane type
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 Safety and Adverse Effects 
 There were no serious ocular events considered to be 
potentially related to intravitreal ranibizumab treatment 
as endophtalmitis, uveitis, vitreous hemorrhage or reti-
nal tears in a total of 631 injections performed. No trau-
matic lens damage was reported, albeit 2 patients changed 
their phakic status during the follow-up and 13 were al-
ready pseudophakics. No long-term effect on intraocular 
pressure was seen. One 78-year-old patient experienced 
a nonfatal stroke 1 month after the seventh injection. 
Another 81-year-old patient suffered from a cavernous 
sinus thromboembolism 6 months after the fifth injec-
tion. One patient died during the second-year study but 
the death was not deemed to be a drug-related adverse 
event.
 Two, 12 and 4 patients withdrew from the study after 
the first, second and third years of follow-up, respective-
ly, because of inability to travel or because they refused 
more treatment.
 Discussion 
 The present study aims to clarify the 36-month out-
comes of intravitreal ranibizumab injections given in an 
as-needed basis and frequent monitoring for CNV sec-
ondary to AMD in the real-world clinical practice. 
Moreover, it was our intention to identify some potential 
prognostic factors that could help us in the better man-
agement of each patient. As far as we know, this is the 
first study describing the 3-year results of intravitreal 
Table 4.  Results of nAMD studies
Study Study design Study
arms
E fficacy end points Treatments
mean change VA from
 baseline/3 months, letters
loss ≥15 letters
% patients
gain ≥15 letters
% patients
MARINA IVR monthly for 0.3 mg +5.4 8 26 24
(24 months time point) [2] 24 months 0.5 mg +6.6 10 33
(n = 716) sham –14.9 47 4
ANCHOR IVR monthly for 0.3 mg +8.1 6 34.3 24
(24 months time point) [3, 4] 24 months 0.5 mg +10.7 4 41.0
(n = 423) PDT –9.8 36 6.3
PIER LD + quarterly IVR 0.3 mg –2.2 21.8 15.0
(24 months time point) [11] (n = 184) 0.5 mg –2.3 18.0 8.2
sham –21.4 41.3 4.8
EXCITE LD + quarterly IVR 0.3 mg +4.9/–1.8 6.7 14.2 5.7
(12 months time point) [12] IVR monthly 0.5 mg +3.8/–2.5 8.5 17.8 5.5
(n = 482) 0.3 mg +8.3/+0.8 5.2 28.7 11.4
PrONTO
(24 months time point) [16]
LD + PRN
(n = 37/40)
n.a. +11.1 2.5 43.0 9.9
SUSTAIN
(12 months time point) [14]
LD + PRN
(n = 513)
n.a. +3.6 7.5 19.3 5.7
SAILOR
(12 months time point) [13]
LD + PRN
(n = 2,378)
n.a. +0.5 to 2.3 14.6–19.3 N/A 3.9–4.6
Gupta et al., 2010
(24 months time point) [5]
TER
(n = 28/76)
n.a. +10 4
(12 months)
32
(12 months)
15.91
Marques et al., 2012
(36 months time point)
PRN
(n = 52/84)
n.a. –1.65 11.7 15.8 8.67
IVR = Intravitreal ranibizumab; PDT = photodynamic therapy; LD = loading dose of 3 monthly injections; n.a. = not applicable; 
TER = treat and extend regimen.
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ranibizumab injections for AMD patients in clinical 
practice.
 Several studies have been developed to understand 
which was the best dosing regimen of ranibizumab in or-
der to attempt VA gains compared to MARINA  [2] and 
ANCHOR  [3, 4] with fewer treatments. The PIER study 
 [12] , the EXCITE study  [13] , the SAILOR study  [14] and 
the SUSTAIN study  [15] , all of them showed poorer re-
sults when compared to MARINA or ANCHOR. Indeed, 
the best results with a nonmonthly regimen were ob-
tained in SUSTAIN in which the patients were evaluated 
every month, suggesting that the efficacy outcomes could 
be maintained with flexible regimens using a frequent 
monitoring. They have reported a gain of +3.6 letters with 
a mean injection rate of 5.7 at 12 months of follow-up. 
Favorable outcomes were also achieved in the small 
PrONTO Study  [16, 17] , a prospective study that used a 
variable-dosing regimen of intravitreal ranibizumab 
based on OCT findings to treat nAMD patients, called 
PRN (pro re nata) regimen. In this trial, a mean visual 
gain similar to that obtained in MARINA and ANCHOR 
( table 4 ) was obtained. After the CATT study  [18] , there 
is a belief that treating with ranibizumab every 4 weeks 
might indeed be equivalent to a treatment ‘as needed’, 
providing an average of 7–8 injections in the first year. 
These kinds of regimen need, however, a close follow-up 
with frequent visits to monitor the response to treatment 
and to treat the recurrent exudation  [18] . Some small se-
ries have been published, in which a ‘treat and extend’ 
regimen was tried, allowing a reduction of office visits, 
with variable results. In this regimen, monthly injections 
were performed until resolution of signs of exudation, 
with the treatment interval sequentially lengthened by 
1–2 weeks or reduced in case of recurrence of exudation. 
A study from Gupta et al.  [5] of 76 eyes reported good re-
sults, comparable to fixed regimens, with a lower mean 
number of office visits ( table 4 ).
 With the increase in the number of diagnosed cases of 
exudative nAMD and the long disease evolution, it is dif-
ficult to maintain a regular monthly follow-up because of 
frequent constraints including missing appointments 
and overbooked clinics.
 In our study, 85% of patients avoided a 15-letter VA 
decrease at 3 years of follow-up, compared to 97.5% of 
such loss in the PrONTO trial and 96% in the treat and 
extend regimen performed by Gupta et al.  [5] , both stud-
ies with 24 months of follow-up. In our study, only 13.0% 
patients gained at least 15 letters of VA at 24 months, 
compared to 26–40% in MARINA/ANCHOR, 43% in the 
PrONTO study, and 15.8% of the eyes gained  6 15 letters 
at 3 years of follow-up. When comparing the proportion 
of patients with 0 or more letters gained at 12 months, we 
have 56.0% and MARINA and ANCHOR revealed 71.3 
and 78% patients with such gains ( table 4 ). In the present 
study, at 12 months, the rate of eyes that stabilized vision 
( ! 5 letters lost) was 66.7% and this was maintained at 24 
months (66.23%) and 36 months (61.54%). Similar results 
were presented by Cohen et al.  [6] that showed an im-
provement of only +0.7 letters (vs. +1.64 letters in our 
study) at 1 year of follow-up with a mean of 3.79 (SD 1.39) 
injections ( table 5 ), similar to the 3.75 (SD 1.2) injections 
performed in our study during the same period. The ret-
rospective analysis included 122 patients and evaluated 
the visual results of ranibizumab injections at 12 months 
of follow-up in a clinical setting. 90.3% of the eyes lost 
fewer than 15 letters and 8% improved by 15 or more let-
ters (compared to 92.9 and 16.6% in our study). Our vi-
sual results seem also to be superior to those reported by 
Rothenbuehler et al.  [7] , another PRN regimen, that re-
ported 55% of patients avoiding a loss of 15 or more letters 
at 24 months (vs. 88% eyes in the present study) despite 
30% of patients showing an improvement of 15 or more 
letters (vs. 13%). In fact, clinical settings are quite differ-
ent from pre-established treatment regimens.
 Some reasons have been pointed out to explain these 
different results. The lack of a loading dose in our study 
was probably a major contributor to the study outcome. 
Evidence of that can be demonstrated analyzing the VA 
improvement pattern during the first 6 months of follow-
Table 5.  Results of nAMD studies
Study V A, letters/NT
12 m onths 24 months 36 months
MARINA [2]
(IVR, 0.5 mg)
+7.2/12 +6.6/24
ANCHOR [3, 4]
(IVR, 0.5 mg)
+11.3/12 +10.7/24
HORIZON [18]
(extension period)
+4.1 +2.0/3.6
PrONTO [15, 16] +9.3/5.6 +11.1/9.9
Gupta et al., 2010 [5] +10/15.91
Cohen et al., 2009 [6] +0.7/3.79
Marques et al., 2012 +1.64/3.75 –1.25/6.36 –1.65/8.67
IVR = Intravitreal ranibizumab; NT = number of treatments.
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up which have been performed here and demonstrated 
that roughly 40% of the subjects had a VA gain during the 
first 6 months that was preserved throughout the study 
period. This raises the question whether a loading dose 
would increase this effect for those patients or for others 
who showed no early VA improvement, and whether or 
not this would have given results closer to those in other 
studies.
 We know from previous already mentioned studies  [6, 
10] that the poorest outcomes were observed when less 
than 5 intravitreal injections per year were used and that 
monthly regular monitoring is required to maintain the 
efficacy benefits. The retreatment criteria adopted in this 
trial were derived from the PrONTO study  [15] with 
some differences. In contrast to the PrONTO study, we 
did not use a cutoff point of 100   m increase in CMT to 
treat but treated every increment or persistence of fluid 
on OCT from previous examinations. However, our re-
sults were far inferior to those presented in the PrONTO 
study. It required strict monthly visits and careful exam-
inations of all the OCT scans in order to detect early signs 
of recurrence attempting VA loss and maximizing the 
benefit. According to this, monthly visits should be kept, 
at least during the first year, and monthly treatment until 
the retina becomes dry. Despite the desired monitoring 
on a 4-week interval basis (or extended intervals as rec-
ommended by the physician), this was not always 
achieved, with some patients having a length in follow-
ups due to patient constraints or overbooked lists. This 
lengthy period between follow-ups can be an important 
cause for the relatively low number of injections per year 
which could be the major cause for this discrepancy in 
the VA outcomes.
 The influences of VA baseline, age, OCT-CMT re-
sponse, number of treatments and CNV lesion type on 
the visual outcomes were also assessed. A predictive val-
ue for better VA was found for: younger age, better base-
line VA, good response on OCT and frequent treatments. 
These findings are in accordance with ANCHOR and 
MARINA studies were it was found that baseline VA, le-
sion size and age were important predictors of final vi-
sual outcomes. Our study reinforces the idea presented in 
the study of Dadgostar et al.  [9] that the visual improve-
ments are related to the frequency of injections received, 
but also to baseline VA. In fact, our worse results could 
be partially explained by the probably suboptimal treat-
ment of our patients. Whereas patients in the PrONTO 
study  [15] underwent a mean of 9.9 injections and in the 
treat and extend regimen study of Gupta et al.  [5]  15.91 
injections in 24 months, our patients had a mean of 6.35 
(SD 2.26, median 6.0) injections during the same 24 
months. The number of treatments decreased after the 
first year from an average of 3.75 (SD 1.20, median 4.0) to 
2.64 and 2.08 in the second and third years, respectively. 
The need for retreatment varied widely among patients 
and it was unpredictable. The correlation found between 
the higher number of injections and a better VA outcome 
could suggest that if the patients were followed up on ex-
actly 4-week periods their outcomes would probably be 
better.
 As proven in this study, a higher baseline VA is also 
an important factor of good visual prognosis. This fact 
reinforces the importance of starting treating the pa-
tients as early as possible. In our department, patients 
with exudative AMD have a privileged access to the first 
injection. This fact allowed us to start the study with a 
mean baseline VA of 49.33 letters, a value above the base-
line VA referred to in other studies in a clinical setting 
 [5, 8] . Nevertheless, at baseline, 16.7% (14 eyes) of our pa-
tients had a BCVA  ! 35 letters, and this fact could help to 
explain our weak results. Having started the treatment 
with a baseline VA of 49.33 letters we achieve, after 3 
years of follow-up and 8.6 injections, a mean VA of 49.52 
letters.
 Loss of VA and the need for retreatment show that the 
disease remains active after the first 2 years. In the third 
year of follow-up, 67.3% of the patients still needed treat-
ment to maintain the macula dry. There is not much in-
formation about the 3-year results in AMD patients treat-
ed with ranibizumab in clinical practice or in clinical tri-
als. The HORIZON study  [19] was an open label extension 
study in patients who completed the 2-year treatment 
phase of MARINA, ANCHOR and FOCUS where Lu-
centis  injections were administered at intervals longer 
than 30 days according to the investigator criteria. At 3 
years of follow-up, after 1 year of PRN regimen, the aver-
age gain in VA was +4.1 letters while at 2 years in this 
flexible regimen the gain decreased to +2.0 letters, thus 
an average decrease of 7 letters. The +2.0 letters gain was 
achieved with a mean of 24 injections plus 3.6 in the 24 
months of the extension period. The natural progression 
of the disease allied to the PRN regimen may have had 
some influence in these long-term results.
 We have tried to find out other predictive factors for a 
better VA outcome. Three different patterns were identi-
fied according to the evolution of VA at 6 months: group 
1 with VA gain and maintenance (39.3%), group 2 with 
initial VA gain that was not maintained (16.7%) and 
group 3 with no initial gain (44%). Although these pat-
terns have been identified at 6 months, it was not possible 
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to find out risk factors that might identify them previ-
ously. In fact, no significant differences were found re-
garding the mean patient’s age, baseline angiographic le-
sion types, baseline VA, baseline CMT measurements or 
number of treatments performed.
 This study has some limitations and potential sources 
of bias. The major limitation is the fact that the eyes in-
cluded in it lack homogeneity. We have included both 
treatment-naive eyes (66 out of 84) and eyes previously 
treated with photodynamic therapy (17 out of 84 eyes). 
This fact did not appear to be significant with no demon-
strable statistical differences in terms of visual outcomes 
between both groups (Student’s t test). Also the fact that 
the study lacks a loading dose is seen as a major limitation 
that could have masked the true efficacy of PRN treat-
ment. Actually, 7 out of 84 patients did receive 3 injec-
tions during the first 3 months but the outcomes were not 
statistically different (given the small sample together 
with a small expected effect size). The study has other 
limitations such as the small sample size, the lack of a 
control group and the fact that it is a retrospective study, 
based on clinical records assessment. Also, we realize that 
11% of the patients had at least 1 missing appointment 
and sometimes it was not possible to run a strict 4-week 
follow-up due to clinical practice constraints. However, 
this fact was handled in a conservative way, using the last 
observation carried forward method, in an attempt not to 
bias the results. Another potential limitation in our trial 
may be found in VA inclusion criteria. No higher or low-
er limits were chosen based on the assumption that all 
included patients could avoid losing initial VA. Patients 
enrolled with poor vision were unlikely to become any 
worse and the lower VA provides room for a bigger im-
provement. The presence of coexisting ocular pathology, 
as expressed in  table 1 , and the time to treatment from 
first diagnosis, which was not considered, may have con-
tributed to our results. In our series, 2 different OCT sys-
tems were used. A high proportion of patients had their 
baseline CMT measured with a Stratus OCT and their 
final CMT measured with a Cirrus OCT. CMT measures 
by Cirrus OCT are greater than by Stratus OCT, yet a 
conversion can be made by subtracting 60   m from the 
value obtained with Cirrus OCT  [11] . So we have to be 
careful with the interpretation of our CMT results as we 
may have introduced some errors.
 In conclusion, this study showed that a flexible treat-
ment regimen based on the actual reality of clinical prac-
tice is able to maintain baseline VA with a reduced num-
ber of injections but results in no VA improvement, at 3 
years of follow-up. This is, we believe, the daily clinical 
practice, where external constraints play a role and par-
tially explain the poor results when comparing with clin-
ical trial results. Doubts remain about whether PRN reg-
imens remain a good choice to treat our patients. These 
results also support the idea that our current criteria for 
PRN regimen based on OCT and VA are not good enough 
to maintain the initial VA gain at 3 years in clinical prac-
tice. Attempts to customize treatment in order to limit 
the number of interventions can actually lead to inade-
quate treatment and insufficient patient care. It is neces-
sary to find out a different regimen, eventually more cus-
tomized, able to treat before a VA decline occurs. Ideally, 
a pattern of retreatment could be found for each patient 
based on previous behavior which could be periodically 
adjusted.
 Hopefully, further studies will be able to identify and 
characterize different predictive parameters for visual re-
sponse to treatment allowing the use of customized treat-
ments while providing the greater benefits.
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